Q Revenue of $0.9 Million, Consistent with Prior Quarter; Year to Date Revenue of $2.5 Million, Growth of 18.3% Compared to Prior Year ~~ Published Interim Analysis from MAINSAIL Study; Post-Market ...
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback